Investment Rating - The report initiates coverage with a "Buy-A" investment rating [4][5]. Core Viewpoints - The company is positioned as a leading domestic ADAS chip manufacturer, focusing on high-level intelligent driving solutions, with significant growth potential driven by the increasing demand for advanced driving assistance systems [1][2]. - The market for intelligent driving chips and algorithms in China is projected to exceed 60 billion RMB by 2030, with a notable shift towards higher-level autonomous driving features [2][39]. - The company has successfully established a strong customer base and competitive advantages through its strategic focus on local service and cost-effectiveness, enabling it to capture a leading market share in the domestic passenger vehicle intelligent driving chip sector [3][13]. Summary by Sections Company Overview - The company has evolved into a leading player in the domestic ADAS chip market since its establishment in 2015, focusing exclusively on intelligent driving since 2019 [1][13]. - By the end of 2024, the company is expected to have shipped over 7 million units of its Journey series chips, achieving a market share of 33.97% in the domestic passenger vehicle intelligent driving chip market [1][13]. Market Potential - The penetration rate of L2 ADAS is nearing its ceiling, while the mid-to-high-level autonomous driving market presents new growth opportunities [2][39]. - The intelligent driving chip market in China is projected to reach approximately 20 billion RMB by 2025 and 50 billion RMB by 2030, with urban NOA chip market space estimated at 150 billion RMB in 2025 and 462 billion RMB in 2030 [2][39]. Competitive Landscape - The company is expected to become a leading third-party high-level intelligent driving solution provider, leveraging its strong strategic and algorithmic capabilities [3][39]. - The competitive landscape is shifting as traditional manufacturers show varying levels of willingness to develop in-house solutions, creating opportunities for the company to expand its market presence [3][39]. Financial Projections - Revenue projections for the company are estimated at 35.2 billion RMB in 2025, 54.8 billion RMB in 2026, and 80.2 billion RMB in 2027, with growth rates of 47.6%, 55.8%, and 46.3% respectively [4][9]. - The target market capitalization for the company is set at 105.5 billion RMB based on a 30x price-to-sales ratio for 2025 [4][8].

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" [7] Core Insights - The treatment of sepsis has significant unmet clinical needs, with recent success in the Phase II clinical trial of STC3141 by Yuan Da Pharmaceutical, marking a breakthrough in sepsis treatment [2][19] - Sepsis is a life-threatening syndrome caused by infection leading to organ dysfunction, with a high mortality rate. In 2017, there were approximately 48.9 million cases globally, resulting in about 11 million deaths [2][21] - Current treatments for sepsis primarily focus on symptomatic care, including antibiotics, vasopressors, and supportive therapies, with no effective curative options available [23] - The market for sepsis treatment is vast due to the severe unmet needs, highlighting the potential for new therapeutic developments [2][21] Summary by Sections 1. Weekly New Drug Market Review - From May 12 to May 16, 2025, the top five companies in the new drug sector by stock price increase were Junshengtai (19.78%), Deqi Pharmaceutical (18.34%), Jiahe Biotech (14.48%), Keji Pharmaceutical (14.46%), and Fuhong Hanlin (12.34%). The top five companies with the largest declines were Gilead Sciences (-17.10%), Canaan Pharmaceuticals (-8.72%), Yunding New Medicine (-7.77%), Zexing Pharmaceutical (-7.18%), and Chuangsheng Group (-6.96%) [1][15] 2. Key Analysis of the New Drug Industry - Sepsis treatment has critical unmet clinical needs, with Yuan Da Pharmaceutical's STC3141 achieving significant clinical endpoints in its Phase II trial in China [2][19] - Sepsis is characterized by a dysregulated host response to infection, leading to organ dysfunction and high mortality rates. Early treatment can improve survival rates [20] - In China, approximately 2.93 million cases of sepsis were reported in 2017, with 709,315 related deaths, indicating a high burden of disease [21] - Current therapies are mainly symptomatic, including antibiotics and supportive care, with no effective treatment options available [23] - The development of new drugs for sepsis is challenging, with many clinical trials failing to meet expectations. However, some therapies, such as STC3141, have shown promising early results [26][31] 3. New Drug Application Approvals and Acceptances - No new drug or new indication applications were approved this week, but eight new drug applications were accepted [4] 4. New Drug Clinical Application Approvals and Acceptances - This week, 40 new drug clinical applications were approved, and 30 new drug clinical applications were accepted [5] 5. Domestic Market Focus Events - Notable events included the initiation of a Phase III trial by BeiGene for its BTK-targeting drug BGB-16673, and the acceptance of new indication applications for drugs by Kelun-Biotech and Zexing Pharmaceutical [11] 6. Overseas Market Focus Events - Key events included AbbVie receiving FDA approval for its c-Met-targeting ADC drug, and GSK's acquisition of Boston Pharmaceuticals for $2 billion [12]

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 33.67 CNY, based on a projected PE of 10.8x for 2025 [4][9][13]. Core Views - The company is positioned as a leading exporter of office furniture, benefiting from a recovery in U.S. home demand and a robust cross-border e-commerce strategy. The integration of multiple quality acquisitions is expected to gradually contribute to performance, with long-term growth prospects remaining strong [9][11][13]. Financial Performance Summary - In 2024, the company achieved a revenue of 11.03 billion CNY, a year-on-year increase of 34.59%, while the net profit attributable to shareholders was 263 million CNY, a slight decrease of 0.02% [1]. - The first quarter of 2025 saw revenues of 2.65 billion CNY, up 12.74% year-on-year, but net profit dropped by 49.49% to 52 million CNY [1]. - The gross margin for 2024 was 18.64%, down 5.15 percentage points year-on-year, primarily due to increased shipping costs [4][11]. Business Segment Performance - The company's OBM (Original Brand Manufacturer) business generated 5.94 billion CNY in revenue in 2024, a significant increase of 76.97%, accounting for 53.86% of total revenue [2]. - International revenue reached 9.89 billion CNY in 2024, a growth of 48.88%, while domestic revenue fell by 27.45% to 1.11 billion CNY [3]. Strategic Initiatives - The company is actively expanding its cross-border e-commerce operations, establishing overseas warehouses for efficient logistics and building independent online platforms to enhance brand visibility [3][8]. - The company is also focusing on a "big home" strategy, upgrading product systems and expanding categories to enhance competitiveness [8][9]. Future Projections - Revenue forecasts for 2025-2027 are projected at 12.72 billion CNY, 14.51 billion CNY, and 16.80 billion CNY, with year-on-year growth rates of 15.30%, 14.07%, and 15.79% respectively [9][11]. - Net profit forecasts for the same period are 390 million CNY, 467 million CNY, and 577 million CNY, with growth rates of 48.44%, 19.53%, and 23.58% respectively [9][11].

Investment Rating - The report assigns a "Buy-A" investment rating to the company [4][9][13] Core Views - The company has shown strong revenue growth, with a 34.59% year-on-year increase in revenue for 2024, reaching 11.03 billion yuan, although net profit slightly declined by 0.02% to 263 million yuan [1] - The company is expanding its cross-border e-commerce operations, with international revenue growing by 48.88% in 2024, while domestic revenue decreased by 27.45% [3][9] - The report anticipates that the company's revenue will continue to grow, projecting revenues of 12.72 billion yuan, 14.51 billion yuan, and 16.80 billion yuan for 2025, 2026, and 2027, respectively, with corresponding net profits of 390 million yuan, 467 million yuan, and 577 million yuan [10][11] Financial Performance - In 2024, the company achieved a gross margin of 18.64%, a decrease of 5.15 percentage points year-on-year, primarily due to increased shipping costs [4][8] - The company’s operating expenses as a percentage of revenue decreased to 13.38% in 2024, down 2.99 percentage points year-on-year [4][7] - The net profit margin for 2024 was 2.41%, a decline of 0.98 percentage points compared to the previous year [7] Market Position and Strategy - The company is positioned as a leading exporter of office furniture, benefiting from a recovery in U.S. home furnishing demand and a robust cross-border e-commerce strategy [9][11] - The company has adopted a dual strategy of "manufacturing overseas and brand expansion," enhancing its logistics efficiency through overseas warehouses and local sales teams in key markets [3][8] - The report highlights the company's proactive measures to mitigate risks associated with U.S. tariffs by diversifying production locations and enhancing operational efficiency [8][9] Valuation - The target price for the company is set at 33.67 yuan, based on a projected price-to-earnings ratio of 10.8x for 2025 [4][9][13] - The report compares the company with peers in the home furnishings export sector, indicating a favorable valuation relative to competitors [13][14]

2025 年 5 月 18 日 电子 台积电积极扩产应对 AI 浪潮，自主芯片国 产化进程提速 台积电先进制程与全球扩产 台积电宣布其 3nm 已进入稳定量产，2nm 制程将于下半年大规模出 货，同时积极扩产封装产能。2024 年起新增 9 座厂区，包含中国台 湾、日本、美国、德国等地，以满足 AI 相关芯片高速成长的需求。 其 2.5D/3D 封装平台 CoWoS 年增幅达 80%，SOIC 年产能翻倍。 小米 SoC 芯片玄戒 O1 将于 5 月下旬发布 小米集团 CEO 雷军宣布，自研手机 SoC 芯片"玄戒 O1"将于 5 月下旬 发布。该芯片预计采用台积电 4nm 工艺，性能对标苹果 A16，标志 国产手机 SoC 芯片正式进入 5nm 以下高端制程行列。目前小米已在 上海和北京分别成立芯片设计公司，研发团队超千人，总投资超 45 亿元。 全球芯片市场结构重塑 市调机构 Omdia 预计，2024 年全球半导体市场规模将达 6830 亿 美元，同比增长 25%。其中 NVIDIA 营收大增 118.6%，首次超越 Intel 成为全球第一大芯片厂；SK 海力士增长近一倍。传统模拟 厂商如英飞凌、意法 ...

Group 1 - The report highlights a "risk-on" environment following the easing of tariffs between China and the US, leading to a significant rebound in global risk assets, particularly in the US stock market [1][9][51] - The A-share market has shown a mixed performance, with the Shanghai Composite Index rising by 0.76% and the ChiNext Index increasing by 1.38%, while the Hang Seng Index fell by 2.09% [1][13] - The report emphasizes the importance of focusing on structural opportunities within the market, particularly in the small-cap sector, which has seen significant gains since the bottom of the "golden pit" [2][26][60] Group 2 - The report notes that the small-cap index and micro-cap stocks have rebounded significantly, with the micro-cap index achieving a 36% increase since the bottom of the "golden pit" [2][60] - It is observed that the performance of sectors closer to the "pit edge" has slowed down, while those further away have experienced larger gains, indicating a rotation in market sentiment [26][30] - The report suggests that the technology sector is expected to continue its recovery, supported by a "second wave" of technology investments, particularly in high-dividend and tech stocks [3][7] Group 3 - The report discusses the impact of external factors, such as the US inflation data and the Federal Reserve's interest rate policies, on market dynamics, indicating a potential delay in rate cuts due to persistent inflation [5][7][9] - The report highlights the importance of monitoring the performance of various sectors, particularly those that have completed their "fill pit" process, such as consumer electronics and machinery, which are now showing signs of recovery [26][27] - The report also emphasizes the need for investors to be cautious of potential downward pressure from unexpected increases in the US dollar index, which could affect market sentiment [2][5] Group 4 - The report outlines the recent trends in fund flows, noting that there has been a significant outflow from major ETFs, indicating a shift in investor sentiment and a potential weakening of support for large-cap indices [20][22][23] - It is noted that the banking sector has shown strong performance, attributed to the influx of incremental capital, which has helped the sector achieve excess returns independent of dividend assets [20][25][26] - The report emphasizes the ongoing structural changes in the public fund industry, with new regulations aimed at enhancing the performance of active equity funds and aligning management fees with fund performance [61][62][63]

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" [7] Core Insights - The treatment of sepsis has significant unmet clinical needs, with recent success in the Phase II clinical trial of STC3141 by Yuan Da Pharmaceutical, marking a breakthrough in sepsis treatment [2][19] - Sepsis is a high-mortality clinical syndrome caused by infection, with an estimated 48.9 million cases and 11 million deaths globally in 2017 according to WHO [2][21] - Current treatments for sepsis primarily focus on symptomatic care, with no effective therapeutic options available [23] - The market for sepsis treatment is vast due to the severe unmet clinical needs, highlighting the potential for new drug developments [2][26] Summary by Sections 1. Weekly New Drug Market Review - From May 12 to May 16, 2025, the top five companies in the new drug sector by stock price increase were Junshengtai (19.78%), Deqi Pharmaceutical (18.34%), Jiahe Biotech (14.48%), Keji Pharmaceutical (14.46%), and Fuhong Hanlin (12.34%) [1][15] - The top five companies by stock price decrease included Gilead Sciences (-17.10%), CanSino Biologics (-8.72%), Yunding New Medicine (-7.77%), Zai Lab (-7.18%), and Chuangsheng Group (-6.96%) [1][15] 2. Key Analysis of the New Drug Industry - Sepsis treatment faces serious unmet clinical needs, with Yuan Da Pharmaceutical's STC3141 achieving clinical endpoints in its Phase II trial in China [2][19] - Sepsis is characterized by a dysregulated host response to infection, leading to life-threatening organ dysfunction [20] - In China, approximately 2.93 million cases of sepsis occur annually, with around 709,315 related deaths [21] - Current therapies are mainly symptomatic, including antibiotics, vasopressors, and supportive care, with no effective treatment options available [23] - The development of new drugs for sepsis is challenging, with many innovative therapies failing in clinical trials [26] 3. New Drug Application Approvals and Acceptances - No new drug or new indication applications were approved this week, but eight new drug applications were accepted [4] 4. New Drug Clinical Application Approvals and Acceptances - This week, 40 new drug clinical applications were approved, and 30 new drug clinical applications were accepted [5] 5. Key Domestic Market Events - Notable events included the initiation of a Phase III trial by BeiGene for its BTK-targeting drug BGB-16673 and the priority review application for a new indication by Kelun-Biotech for SKB264 [11] 6. Key Overseas Market Events - AbbVie announced FDA approval for its c-Met-targeting ADC drug Telisotuzumab Vedotin, marking a significant milestone in the treatment of non-small cell lung cancer [12]

2025 年 05 月 18 日 房地产 信阳全面推行现房销售 周观点：现房销售逐步推进 信阳住建局印发《关于加强商品房预售管理工作的若干措施（试行） 的批前公示》，要求严控预售条件许可，规范预售资金使用。同时， 明确文件印发后新出让土地开发的商品房，一律实行现房销售。 我们认为，当前发展房地产行业新发展模式下，现房销售作为构建新 发展模式中的环节之一，将逐步试点推进，改善当前房地产市场供需 环境，增强居民购房信心。建议关注困境反转类房企：金地集团、新 城控股等；保持拿地强度的龙头招商蛇口、绿城中国、保利发展、滨 江集团等；多元经营稳健发展的地方国企浦东金桥、外高桥等。 销售回顾（5.10-5.16） 重点监测 32 城合计成交总套数为 1.6 万套，环比上周增长 27.3%； 2025 年累计成交总套数为 29.6 万套，累计同比下降 2.6%。其中，一 线城市成交 5319 套，环比上周增长 43.6%，2025 年累计成交 8.5 万 套，累计同比增长 13%；二线城市成交 9045 套，环比上周增长 22%， 2025 年累计成交 17.6 万套，累计同比下降 8.9%；三线城市成交 1966 套，环 ...

2025 年 05 月 18 日 或仅是整理，蓄势以待机 本期要点：或仅是整理，蓄势以待机 上期提到，全天候模型发出了技术面上的风险提示信号，从这个角度 看未来一段时间市场或将进入技术上的震荡整理期。事后来看，走势 基本符合预期。 对于大盘，从走势形态看，本轮反弹已经涨了两波，第二波是从五一 之后开始的。从周期分析模型对不同级别趋势的监控分析结果来看， 当前潜在的调整仅是针对于五一之后上涨过程的调整，而四月初以来 的上行趋势或并没有已经结束的充分证据。从这个角度看，本轮调整 或最多回到 4 月底 5 月初的震荡区间，随后有望重新开始一波上行 走势，只有在那波上行趋势再次衰竭的时候才能判断本轮反弹是否真 正结束了。 在当前潜在的蓄势震荡过程中，四轮驱动模型建议关注军工、家电、 农林牧渔、汽车、电子、计算机、非银等板块。整体风格上可以适当 偏小盘，结构上可以适当偏均衡一些。 风险提示：根据历史数据构建的模型在市场变化时可能失效。 金融工程定期报告 证券研究报告 杨勇 分析师 SAC 执业证书编号：S1450518010002 yangyong1@essence.com.cn 相关报告 结构重于仓位，继续关注先 进 ...

Investment Rating - The report assigns a "Buy-A" investment rating to the company with a 12-month target price of 399.56 CNY [4][7]. Core Views - The report highlights the potential of the company's EGFR×HER3 bispecific antibody ADC in the overseas market, especially due to its collaboration with BMS, which is expected to drive significant sales growth [1][2]. - The company has established a strong pipeline in ADC and bispecific antibody fields, with multiple innovative products entering clinical stages, indicating promising future developments [1][3]. Summary by Sections Company Overview - The company is positioned as an innovative drug development enterprise with a global perspective, focusing on ADC and bispecific antibody platforms. It has 15 candidate drugs in clinical stages and over 80 clinical trials globally [12]. Core Product - The core product, BL-B01D1, is the world's first EGFR×HER3 bispecific antibody ADC, currently in collaboration with BMS. The product has shown excellent clinical data and is in advanced clinical trials both domestically and internationally [2][3]. ADC Pipeline - The company has eight ADC drugs in clinical development, including BL-M07D1, which is in phase 3 trials. New generation linker-payload drugs BL-B16D1 and BL-M17D1 have also entered clinical stages [3][21]. Financial Projections - Revenue is expected to improve significantly from 2024 onwards, primarily due to the collaboration with BMS, which includes an upfront payment of 800 million USD and potential milestone payments [21][31]. - The company has faced losses in recent years due to heavy investments in R&D, but profitability is anticipated to improve as core products progress towards commercialization [21][22]. R&D Investment - R&D expenses have increased significantly, reaching 744 million CNY in 2023, with a projected 1.443 billion CNY in 2024, reflecting the company's commitment to advancing its clinical pipeline [27][28]. Management Team - The management team comprises experienced professionals from various fields, providing strong leadership and expertise in drug development and commercialization [15][16]. Market Position - The company has a concentrated ownership structure, with the top ten shareholders holding 88.36% of the shares, indicating strong control by core stakeholders [18][19]. Clinical Development Strategy - The company is actively pursuing overseas development through collaborations with multinational corporations and its subsidiary SystImmune, enhancing its global reach [31][32].